Calmodulin is a selective modulator of estrogen receptors

被引:0
作者
Pedrero, JMG
Del Rio, B
Martínez-Campa, C
Muramatsu, M
Lazo, PS
Ramos, S [1 ]
机构
[1] Univ Oviedo, Dept Bioquim & Biol Mol, Inst Oncol Principado Asturias, Oviedo 33007, Spain
[2] Saitama Med Sch, Dept Biochem, Moroyama, Saitama 35004, Japan
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the search for differences between ERalpha and ERbeta, we analyzed the interaction of both receptors with calmodulin (CaM) and demonstrated that ERa but not ERbeta directly interacts with CaM. Using transiently transfected HeLa cells, we examined the effect of the CaM antagonist N-(6-aminohexyl)-5-chloro-naphthalene sulfonilamide hydrochloride (W7) on the transactivation properties of ERalpha and ERbeta in promoters containing either estrogen response elements or activator protein 1 elements. Transactivation by ERalpha was dose-dependently inhibited by W7, whereas that of ERbeta was not inhibited or even activated at low W7 concentrations. In agreement with these results, transactivation of an estrogen response element containing promoter in MCF-7 cells (which express a high ERalpha/ERbeta ratio) was also inhibited by W7. In contrast, transactivation in T47D cells (which express a low ERalpha/ERbeta ratio) was not affected by this CaM antagonist. The sensitivity of MCF-7 cells to W7 was abolished when cells were transfected with increasing amounts of ER(3, indicating that the sensitivity to CaM antagonists of estrogen-responsive tissues correlates with a high ERalpha/ERbeta ratio. Finally, substitution of lysine residues 302 and 303 of ERa for glycine rendered a mutant ERa unable to interact with CaM whose transactivation activity became insensitive to W7. Our results indicate that CaM antagonists are selective modulators of ER able to inhibit ERalpha-mediated activity, whereas ERbeta actions were not affected or even potentiated by W7.
引用
收藏
页码:947 / 960
页数:14
相关论文
共 46 条
  • [1] Calmodulin is essential for estrogen receptor interaction with its motif and activation of responsive promoter
    Biswas, DK
    Reddy, PV
    Pickard, M
    Makkad, B
    Pettit, N
    Pardee, AB
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (50) : 33817 - 33824
  • [2] An estrogen receptor-Lu splicing variant mediates both positive and negative effects on gene transcription
    Bollig, A
    Miksicek, RJ
    [J]. MOLECULAR ENDOCRINOLOGY, 2000, 14 (05) : 634 - 649
  • [3] MODULATION OF ESTRADIOL AND DNA-BINDING TO ESTROGEN-RECEPTOR UPON ASSOCIATION WITH CALMODULIN
    BOUHOUTE, A
    LECLERCQ, G
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 208 (02) : 748 - 755
  • [4] Synergism of cytotoxic effects of vinorelbine and paclitaxel in vitro
    Budman, DR
    Calabro, A
    Wang, LG
    Liu, XM
    Stiel, L
    Adams, LM
    Kreis, W
    [J]. CANCER INVESTIGATION, 2000, 18 (08) : 695 - 701
  • [5] Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway
    Caelles, C
    González-Sancho, JM
    Muñoz, A
    [J]. GENES & DEVELOPMENT, 1997, 11 (24) : 3351 - 3364
  • [6] Campbell-Thompson M, 2001, CANCER RES, V61, P632
  • [7] INVITRO INTERACTION OF ESTRADIOL-RECEPTOR WITH CA-2+-CALMODULIN
    CASTORIA, G
    MIGLIACCIO, A
    NOLA, E
    AURICCHIO, F
    [J]. MOLECULAR ENDOCRINOLOGY, 1988, 2 (02) : 167 - 174
  • [8] INTERACTION OF PROTEINS WITH TRANSCRIPTIONALLY ACTIVE ESTROGEN-RECEPTORS
    CAVAILLES, V
    DAUVOIS, S
    DANIELIAN, PS
    PARKER, MG
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (21) : 10009 - 10013
  • [9] Clarke R, 2001, PHARMACOL REV, V53, P25
  • [10] Estrogen receptor null mice: What have we learned and where will they lead us?
    Couse, JF
    Korach, KS
    [J]. ENDOCRINE REVIEWS, 1999, 20 (03) : 358 - 417